BN/SsN |
blood CD4 cell count to CD8 cell count ratio |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
CD4-positive T cell quantity |
both |
132 days-139 days |
211 |
2690.0 |
% |
17.83 |
259.0 |
automated differential white blood cell count test |
0 |
|
0 |
|
|
|
65889 |
114 |
BN/SsN |
calculated serum anti-rat type 2 collagen autoantibody titer |
type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) |
Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 |
blood autoantibody amount |
both |
66 days-126 days |
13 |
2.0 |
null |
0.55 |
2.0 |
enzyme linked immunosorbent assay |
0.0 |
immunized |
10 |
days |
variable |
titer |
69965 |
850 |
BN/SsN |
blood CD4 cell count |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
CD4-positive T cell quantity |
both |
132 days-139 days |
203 |
3.14 |
x 1000 cells/ul |
0.06 |
0.79 |
automated differential white blood cell count test |
0 |
|
0 |
|
|
|
65881 |
114 |
BN/SsN |
calculated serum anti-rat type 2 collagen autoantibody titer |
Freund's incomplete adjuvant (50 %) and type II collagen (2 mg/kg) |
Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 |
blood autoantibody amount |
female |
66 days-126 days |
7 |
1.9 |
null |
0.68 |
1.8 |
enzyme linked immunosorbent assay |
0.0 |
|
0 |
|
|
titer |
69928 |
1241 |
BN/SsN |
calculated serum anti-porcine type 2 collagen antibody titer |
type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) |
Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 |
blood immunoglobulin amount |
both |
66 days-126 days |
13 |
3.0 |
null |
0.55 |
2.0 |
enzyme linked immunosorbent assay |
0.0 |
immunized |
10 |
days |
variable |
titer |
69964 |
850 |
BN/SsN |
white blood cell count |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
leukocyte quantity |
both |
132 days-139 days |
207 |
9.6 |
x 1000 cells/ul |
0.16 |
2.34 |
automated total white blood cell count test |
0 |
|
0 |
|
|
|
65870 |
114 |
BN/SsN |
blood glucose level |
glucose solution (2 g/kg) |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
blood glucose amount |
both |
118 days-125 days |
220 |
116.64 |
mg/dl |
1.5 |
22.32 |
intraperitoneal glucose tolerance test |
0 |
glucose injection |
120 |
min |
|
|
65981 |
114 |
BN/SsN |
platelet count |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
platelet quantity |
both |
132 days-139 days |
208 |
1037.0 |
x 1000 /ul |
3.47 |
50.0 |
automated blood cell counting method |
0 |
|
0 |
|
|
|
65927 |
114 |
BN/SsN |
both adrenal glands weight to body weight ratio |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
adrenal gland mass |
both |
167 days-174 days |
210 |
25.1 |
mg/100g |
0.16 |
2.3 |
post excision weight measurement |
0 |
|
0 |
|
|
|
65992 |
114 |
BN/SsN |
heart weight to body weight ratio |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
heart mass |
both |
167 days-174 days |
45 |
3.4 |
g/kg |
0.02 |
0.13 |
post excision weight measurement |
0 |
|
0 |
|
|
|
65998 |
114 |
BN/SsN |
percentage of study population developing chronic experimental arthritis during a period of time |
Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days) |
Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 |
joint integrity trait |
female |
66 days-126 days |
7 |
0.0 |
% |
|
|
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
69924 |
1241 |
BN/SsN |
percentage of study population developing experimental arthritis during a period of time |
type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) |
Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 |
joint integrity trait |
both |
66 days-126 days |
13 |
0.0 |
% |
|
|
in vivo visual assessment |
0.0 |
immunized |
10 |
days |
variable |
|
69961 |
850 |
BN/SsN |
blood neutrophil count |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
neutrophil quantity |
both |
132 days-139 days |
216 |
2.36 |
x 1000 cells/ul |
0.05 |
0.69 |
automated differential white blood cell count test |
0 |
|
0 |
|
|
|
65874 |
114 |
BN/SsN |
blood CD8 cell count |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
CD8-positive T cell quantity |
both |
132 days-139 days |
200 |
0.12 |
x 10E6 cells/ml |
0.0 |
0.02 |
automated differential white blood cell count test |
0 |
|
0 |
|
|
|
65885 |
114 |
BN/SsN |
blood hemoglobin level |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
blood hemoglobin amount |
both |
132 days-139 days |
208 |
17.2 |
g/dl |
0.01 |
0.2 |
automated blood cell counting method |
0 |
|
0 |
|
|
|
65915 |
114 |
BN/SsN |
white blood cell count |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
leukocyte quantity |
both |
132 days-139 days |
208 |
7.2 |
x 1000 cells/ul |
0.08 |
1.2 |
automated total white blood cell count test |
0 |
|
0 |
|
|
|
65939 |
114 |
BN/SsN |
percentage of study population developing chronic experimental arthritis during a period of time |
Freund's incomplete adjuvant (50 %) (between 1 and 7 days) and type II collagen (2 mg/kg) (between 1 and 7 days) then Freund's incomplete adjuvant (50 %) (between 1 and 35 days) and type II collagen (100 ug) (between 1 and 35 days) |
Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 |
joint integrity trait |
male |
66 days-126 days |
13 |
0.0 |
% |
|
|
in vivo visual assessment |
0.0 |
|
0 |
|
|
|
69923 |
1241 |
BN/SsN |
body weight loss |
type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) |
Griffiths MM, et al., Arthritis Rheum 2000 Jun;43(6):1278-89 |
body mass |
both |
66 days-126 days |
13 |
0.0 |
% |
0.0 |
0.0 |
body weighing method |
0.0 |
immunized |
10 |
days |
variable |
(weight loss) |
69958 |
850 |
BN/SsN |
calculated serum anti-rat type 2 collagen autoantibody titer |
Freund's incomplete adjuvant (50 %) and type II collagen (2 mg/kg) |
Furuya T, et al., Hum Mol Genet 2000 Sep 22;9(15):2241-50 |
blood autoantibody amount |
male |
66 days-126 days |
13 |
1.3 |
null |
0.28 |
1.0 |
enzyme linked immunosorbent assay |
0.0 |
|
0 |
|
|
titer |
69927 |
1241 |
BN/SsN |
blood glucose level |
glucose solution (2 g/kg) |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
blood glucose amount |
both |
118 days-125 days |
220 |
156.42 |
mg/dl |
3.48 |
51.66 |
intraperitoneal glucose tolerance test |
0 |
glucose injection |
30 |
min |
|
|
65975 |
114 |
BN/SsN |
blood CD25 cell count to CD4 cell count ratio |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
regulatory T cell quantity |
both |
132 days-139 days |
215 |
18.6 |
% |
0.12 |
1.71 |
automated differential white blood cell count test |
0 |
|
0 |
|
|
|
65902 |
114 |
BN/SsN |
hematocrit |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
erythrocyte quantity |
both |
132 days-139 days |
208 |
52.4 |
% |
0.11 |
1.6 |
automated blood cell counting method |
0 |
|
0 |
|
|
|
65909 |
114 |
BN/SsN |
mean corpuscular volume |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
erythrocyte size trait |
both |
132 days-139 days |
208 |
55.3 |
fl |
0.1 |
1.4 |
automated blood cell counting method |
0 |
|
0 |
|
|
|
65921 |
114 |
BN/SsN |
red blood cell count |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
erythrocyte quantity |
both |
132 days-139 days |
208 |
9.47 |
x 10E6 cells/ul |
0.01 |
0.13 |
automated blood cell counting method |
0 |
|
0 |
|
|
|
65933 |
114 |
BN/SsN |
blood glucose level |
glucose solution (2 g/kg) |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
blood glucose amount |
both |
118 days-125 days |
220 |
108.54 |
mg/dl |
1.02 |
15.12 |
intraperitoneal glucose tolerance test |
0 |
glucose injection |
0 |
min |
|
|
65945 |
114 |
BN/SsN |
systolic blood pressure |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
arterial blood pressure trait |
both |
125 days-132 days |
220 |
137.0 |
mmHg |
1.08 |
16.0 |
tail cuff piezoplethysmography |
|
|
0 |
|
6-8 readings per sitting |
|
11670 |
114 |
BN/SsN |
both adrenal glands wet weight |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
adrenal gland mass |
both |
167 days-174 days |
210 |
58.0 |
mg |
0.37 |
5.3 |
post excision weight measurement |
0 |
|
0 |
|
|
|
65985 |
114 |
BN/SsN |
body weight |
control condition |
Johannesson M, et al., Genome Res. 2009 Jan;19(1):150-8 |
body mass |
both |
70 days
| 220 |
246.1 |
g |
0.55 |
8.1 |
body weighing method |
0 |
|
0 |
|
|
|
66006 |
114 |